Triple
T10292093
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CD38 |
E241387
|
entity |
| Predicate | targetOf |
P860
|
FINISHED |
| Object |
TAK-079
TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
|
E852350
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: TAK-079 | Statement: [CD38, targetOf, TAK-079]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: TAK-079 Context triple: [CD38, targetOf, TAK-079]
-
A.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
B.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
E.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: TAK-079 Triple: [CD38, targetOf, TAK-079]
Generated description
TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: TAK-079 Target entity description: TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
-
A.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
B.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
E.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381aaafc08190af475ef58dc16aba |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d4d2d35f048190a215493acdf1f718 |
completed | April 7, 2026, 9:48 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d6f85dcbac8190a2ac66354010e328 |
completed | April 9, 2026, 12:52 a.m. |
| NEDg | Description generation | batch_69d6fcaee26c8190a19f7d07a63531f6 |
completed | April 9, 2026, 1:11 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69d6fd879ab88190b0a47295f5d7ad4d |
completed | April 9, 2026, 1:14 a.m. |
Created at: April 6, 2026, 11:42 a.m.